Skip to main content
. Author manuscript; available in PMC: 2020 Jan 13.
Published in final edited form as: Mol Cancer Ther. 2012 May 2;11(7):1400–1410. doi: 10.1158/1535-7163.MCT-12-0172

Figure 1.

Figure 1.

Binding and competition ELISA. A, binding of IgG1 m610.27 and m630.3Fc to hIGF-II, hIGF-I, and human insulin. B, binding of the antibodies to mIGF-II. C, competition of m630.3Fc with IgG1s m610.27 and m708.5 in binding to hIGF-II. D, competition of m630.3Fc with IgG1s m610.27 and m708.5 in binding to mIGF-II. E, binding of m660 to hIGF-II. F, binding of m660 to long hIGF-II. G, competition of the antibodies with IGFBP2 in binding to hIGF-II. H, competition of the antibodies with IGFBP3 in binding to hIGF-II. All assays were done in duplicate. Error bars were included in all binding curves.